Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Myelodysplastic Syndromes 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Cholangiocarcinoma 3

Interventions

pembrolizumab 45Paclitaxel 8Cisplatin 8Carboplatin 8lenvatinib 7Pemetrexed 5Gemcitabine 4camrelizumab 3Docetaxel 3Capecitabine 3epacadostat 2avelumab 2Fluorouracil 2Cetuximab 2Acetaminophen 2vicriviroc 1sinoporphyrin sodium 1penpulimab 1olaparib 1etoposide phosphate 1enzalutamide 1balstilimab 1apatinib 1Temozolomide 1Tadalafil 1Standard of Care 1Serotonin 5-HT3 Receptor Antagonists 1Radiotherapy 1Radiosurgery 1Poly(ADP-ribose) Polymerase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Injections × Clear all
NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Women's Hospital School Of Medicine Zhejiang University

Phase 2 Unknown
20 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡